Literature DB >> 31576336

Testing two (of several) intravenous iron dosing strategies in hemodialysis.

Margaret K Yu1, Glenn M Chertow1.   

Abstract

Entities:  

Year:  2019        PMID： 31576336      PMCID： PMC6685907          DOI： 10.21037/atm.2019.05.75

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Time-dependent associations between iron and mortality in hemodialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Deborah L Regidor; Charles J McAllister; Beckie Michael; David G Warnock
Journal:  J Am Soc Nephrol       Date:  2005-07-20       Impact factor: 10.121

2.  Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

Authors: 
Journal:  N Engl J Med       Date:  2019-01-14       Impact factor: 91.245

3.  Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.

Authors:  George R Bailie; Maria Larkina; David A Goodkin; Yun Li; Ronald L Pisoni; Brian Bieber; Nancy Mason; Lin Tong; Francesco Locatelli; Mark R Marshall; Masaaki Inaba; Bruce M Robinson
Journal:  Kidney Int       Date:  2014-07-30       Impact factor: 10.612

4.  Trends in intravenous iron use among dialysis patients in the United States (1994-2002).

Authors:  Wendy L St Peter; Gregorio T Obrador; Tricia L Roberts; Allan J Collins
Journal:  Am J Kidney Dis       Date:  2005-10       Impact factor: 8.860

5.  Comparative mortality risk of anemia management practices in incident hemodialysis patients.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Jerry Avorn; Brian D Bradbury; Jun Liu; Wolfgang C Winkelmayer
Journal:  JAMA       Date:  2010-03-03       Impact factor: 56.272

6.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

Review 7.  Worldwide access to treatment for end-stage kidney disease: a systematic review.

Authors:  Thaminda Liyanage; Toshiharu Ninomiya; Vivekanand Jha; Bruce Neal; Halle Marie Patrice; Ikechi Okpechi; Ming-hui Zhao; Jicheng Lv; Amit X Garg; John Knight; Anthony Rodgers; Martin Gallagher; Sradha Kotwal; Alan Cass; Vlado Perkovic
Journal:  Lancet       Date:  2015-03-13       Impact factor: 79.321

Review 8.  Iron requirements in hemodialysis.

Authors:  John A Sargent; Sergio R Acchiardo
Journal:  Blood Purif       Date:  2004       Impact factor: 2.614

9.  Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.

Authors:  Joshua Zaritsky; Brian Young; He-Jing Wang; Mark Westerman; Gordana Olbina; Elizabeta Nemeth; Tomas Ganz; Seth Rivera; Allen R Nissenson; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

Review 10.  Iron and thrombosis.

Authors:  Massimo Franchini; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  Ann Hematol       Date:  2007-12-08       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.